相关实验视频

Updated: Jul 27, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

直肠腺癌:ex vivo 9.4T MRI-相关性与对新辅助化学或放射治疗的基因病理治疗反应

Zhihui Li¹, Yuan Yuan², Minglu Liu²

¹Department of Radiology, Ruijin Hospital Luwan Branch, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Cancer medicine

|August 1, 2024

概括

在新辅助化学放射治疗 (nCRT) 后,ex vivo 9.4T MRI 准确评估了直肠腺癌的治疗反应. 这种高场成像为评估瘤回归度 (TRG) 与3.0TMRI相比提供了更好的细节.

科学领域:

放射学和成像科学放射学和成像科学
瘤学研究研究
胃肠道病理胃肠道病理

背景情况:

新辅助化学放射疗法 (nCRT) 是局部晚期直肠癌 (LARC) 的标准治疗方法.
准确评估治疗反应对于指导后续管理和预测结果至关重要.
活体MRI提供了一个可控的环境,用于对切除的标本进行详细的评估.

研究的目的:

通过使用ex vivo 9.4T MRI评估直肠腺癌中对nCRT治疗反应的成像特征.
确定9.4TMRI用于评估瘤回归度 (TRG) 的诊断性能,与3.0TMRI和病理发现相比.

主要方法:

包括15名用nCRT和彻底手术治疗的LARC病例.
切除的标本使用3.0T和9.4TMRI系统进行了ex vivo扫描.
评估了残留瘤深度和基于MRI的TRG,并与组织病理学进行了比较.

主要成果:

没有脂肪抑制的ex vivo 9.4T T2WI有效区分瘤,纤维化和正常的直肠壁组织.
精确的TRG评估在9.4TMRI的86.7%标本中实现,而3.0TMRI的73.3%.
9.4T磁力共振成像显示了直肠壁组件和治疗反应的优异可视化.

结论:

活体外9.4TMRI可提供直肠壁部件的清晰成像,并为评估nCRT响应提供出色的诊断性能.
这种高场核磁共振技术可以更准确地评估LARC患者在nCRT后的TRG.
9.4TMRI具有重要的潜力,用于对直肠腺癌的详细治疗后评估.

关键词:

它们是ex vivo,ex vivo.磁共振成像技术的使用病理性瘤回归回归.这是直肠癌.

更多相关视频

Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model

Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model

Published on: April 18, 2015

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...